GGrantIndex
← Leaderboards

Lacey R McNally

University Of Oklahoma Hlth Sciences Ctr

$8,482,397
Attributed
$10,878,838
Total exposure
10
Grants
9
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.3M · FY200925
$2.5M$1.9M$1.3M$625K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$10,878,838 · 10

By mechanism

R01$9,470,981 · 5
R00$710,099 · 1
R21$362,664 · 1
K99$180,000 · 1
P30$155,094 · 2

Top collaborators

Most similar at University Of Oklahoma Hlth Sciences Ctr

Same institution · by research overlap

Others in their field

Top investigators on “In Vivo

Research focus

In VivoMalignant NeoplasmsContrast MediaTumorImageOptoacoustic TomographyResponseDyesDetectionIn VitroBiodistributionTissuesClinical TrialsMolecularNeoplasm MetastasisMalignant Neoplasm Of PancreasChemotherapyPharmaceutical PreparationsSignal TransductionDoseExcisionImaging ModalityExtracellularNeoplastic Cell

Grant awards (32)

Development of contrast agents to facilitate image-guided surgery$1,728,268
R01 · FY2025 · CA · contact PI
Development of an apoptosis biosensor for monitoring of breast cancer$533,998
R01 · FY2025 · EB · contact PI
Cancer Therapeutics Program$50,338
P30 · FY2025 · CA · contact PI
Development of contrast agents to facilitate image-guided surgery$563,640
R01 · FY2024 · CA · contact PI
Development of an apoptosis biosensor for monitoring of breast cancer$502,136
R01 · FY2024 · EB · contact PI
Non-invasive assessment of graft vs host disease using optoacoustic imaging$193,195
R21 · FY2024 · CA
Cancer Therapeutics Program$52,379
P30 · FY2024 · CA · contact PI
Development of contrast agents to facilitate image-guided surgery$607,029
R01 · FY2023 · CA · contact PI
Development of an apoptosis biosensor for monitoring of breast cancer$495,147
R01 · FY2023 · EB · contact PI
Non-invasive assessment of graft vs host disease using optoacoustic imaging$169,469
R21 · FY2023 · CA
Cancer Therapeutics Program$52,377
P30 · FY2023 · CA · contact PI
Stroma Targeted Theranostic Nanoparticles for Pancreatic Cancer$327,188
R01 · FY2021 · CA · contact PI
Non-Invasive Detection of Tumor Extracellular pH using Multispectral Optoacoustic Tomography$321,146
R01 · FY2021 · CA · contact PI
Stroma Targeted Theranostic Nanoparticles for Pancreatic Cancer$327,188
R01 · FY2020 · CA · contact PI
Non-Invasive Detection of Tumor Extracellular pH using Multispectral Optoacoustic Tomography$323,588
R01 · FY2020 · CA · contact PI
Theranostic Nanoparticles For Detection and Treatment of Pancreatic Cancer$353,654
R01 · FY2019 · EB · contact PI
Non-invasive detection of tumor extracellular pH using multispectral optoacoustic tomography$342,238
R01 · FY2019 · CA · contact PI
Stroma targeted theranostic nanoparticles for pancreatic cancer$330,847
R01 · FY2019 · CA · contact PI
Theranostic nanoparticles for detection and treatment of pancreatic cancer$378,267
R01 · FY2018 · EB · contact PI
Non-invasive detection of tumor extracellular pH using multispectral optoacoustic tomography$354,563
R01 · FY2018 · CA · contact PI
Stroma targeted theranostic nanoparticles for pancreatic cancer$354,563
R01 · FY2018 · CA · contact PI
Deep Learning in the context of Multispectral optoacoustic tomography Administrative supplement$133,300
R01 · FY2018 · EB · contact PI
Theranostic nanoparticles for detection and treatment of pancreatic cancer$394,421
R01 · FY2017 · EB · contact PI
Stroma targeted theranostic nanoparticles for pancreatic cancer$354,563
R01 · FY2017 · CA · contact PI
Theranostic nanoparticles for detection and treatment of pancreatic cancer$392,891
R01 · FY2016 · EB · contact PI
Non-invasive detection of tumor extracellular pH using multispectral optoacoustic tomography$318,294
R01 · FY2016 · CA · contact PI
Non-invasive detection of tumor extracellular pH using multispectral optoacoustic tomography$34,052
R01 · FY2016 · CA · contact PI
KiSS1 treatment of pancreatic adenocarcinoma$227,040
R00 · FY2013 · CA · contact PI
KiSS1 treatment of pancreatic adenocarcinoma$241,530
R00 · FY2012 · CA · contact PI
KiSS1 treatment of pancreatic adenocarcinoma$241,529
R00 · FY2011 · CA · contact PI
KiSS1 treatment of pancreatic adenocarcinoma$90,000
K99 · FY2010 · CA · contact PI
KiSS1 treatment of pancreatic adenocarcinoma$90,000
K99 · FY2009 · CA · contact PI